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Introduction
Extrinsic signaling molecules have been widely examined for their potential to support hematopoietic stem cells (HSCs) ex vivo. However, few growth factors have been identified that maintain the primitive properties of HSCs. 1, 2 Recently, several proteins or small molecules were shown to increase the numbers of cultured human hematopoietic stem-and progenitor cells (HSPCs), but the majority of these rely on the basic support of at least three different cytokines, [3] [4] [5] [6] [7] [8] some of which may promote differentiation at the expense of HSC maintenance. 1, 2, 9 Thus, current culture conditions for HSPCs should be improved by novel HSC-supportive factors. Using a systematic screening approach, we have identified chemokine (C-C motif) ligand 28 (CCL28) as a promising new growth factor that preserves the functional integrity of human HSPCs.
Methods

Culture conditions and progenitor cell assays
HSPCs were cultured in Serum-Free Expansion Medium (StemCell Technologies) supplemented with stem cell factor (SCF) at 10 ng/mL ("S10") or 100 ng/mL ("S100"). For screening (n=276) and validation (n=36), recombinant cytokines (Peprotech) were used at 100 ng/mL. Colony forming cell (CFC) assays were established according to manufacturer's instructions (StemCell Technologies). Longterm culture-initiating cell (LTC-IC) assays are described elsewhere. 10 
Statistical analyses
Statistical significance was calculated using paired t-test. Unless otherwise stated, error bars indicate standard error of the mean (SEM).
Results and discussion
To discover novel growth factors for HSPCs, we designed a screening assay for expansion of CB-derived CD34 + cells based on high-throughput FACS analysis of CD34 expression following a 7-day culture period. Given the high proliferative potential of CB progenitors, [11] [12] [13] we hypothesized that the power of each factor would be best distinguished in low concentrations of SCF, which promotes survival without provoking extensive proliferation. 14, 15 A concentration of 10 ng/mL SCF was sufficient to maintain survival and induce strong synergistic effects on CD34 + cell expansion together with the known HSC-supportive factor thrombopoietin (TPO) 16 ( Figure S1A ). Thus, we used this condition to systematically screen 276 human growth factors for their potential to expand CD34 + cells ( Figure 1A ). Based on two independent screens (Table S1E ) and three consecutive validation experiments ( Figure 1B and S1B), CCL28 showed the most prominent and consistent expansion of CD34 + cells, and was therefore selected for further investigation.
To determine the contexts in which CCL28 stimulates HSPCs, we first evaluated the effect of increasing CCL28 doses at different SCF concentrations. We observed a dose-dependent increase in CD34 + cell numbers in response to stimulation with 50-1000 ng/mL CCL28 ( Figure 1C and S3B). At 500 ng/mL the effect of CCL28 reached saturation and yielded similar synergistic effects on CD34 + cell expansion as TPO ( Figure 1C and S2). Bone marrow (BM)-and fetal liver (FL)-derived CD34 + cells were stimulated in a similar manner ( Figure 1D ). CFC assays showed that CCL28, similarly to TPO, induced a robust expansion of functional progenitor cells together with SCF ( Figure 1E and S3A). CCL28 also promoted growth, but to a lesser extent, in combination with TPO or fms-like tyrosine kinase 3 ligand (FLT3L) ( Figure S3C -D). When added alone, CCL28 failed to induce a net proliferation of CD34 + cells, but was sufficient to maintain progenitor activity ( Figure 1F -G), suggesting that it provides crucial survival signals for primitive hematopoietic cells.
To understand the basis of the cellular response to CCL28 stimulation, we performed transcriptional profiling and gene set enrichment analysis (GSEA). 17 Treatment with either CCL28 ( Figure 1H ) or TPO ( Figure S4 ) caused a significant enrichment of genes correlating with the GO term cell cycle. Genes associated with cell viability were significantly enriched in CCL28-stimulated cells, but not in cells treated with TPO ( Figure 1H and S4). The gene expression signatures translated into effects on cell cycling with higher frequencies of dividing cells following CCL28 and TPO stimulation ( Figure 1I and K). Moreover, we observed a trend towards decreased apoptosis in CCL28 stimulated cells ( Figure 1J and L). Thus, CCL28 supports proliferation of hematopoietic progenitors by stimulating cell cycling and by suppressing apoptosis.
CCL28 signals through the two cell surface receptors CCR3 and CCR10. 18, 19 We detected CCR10, but not CCR3, expression in the vast majority of CD34 + cells and in the HSC-enriched CD34 + CD38population (Figure 2A ), suggesting that CCL28 operates through CCR10 on the earliest hematopoietic progenitors. To assess whether CCL28 indeed supports the most immature fraction of HSPCs, we performed LTC-IC assays, which showed preserved LTC-IC activity of CCL28-treated cultures, as compared to starting equivalents of fresh cells ( Figure 2B -C). These results prompted us to investigate the impact of CCL28 treatment on growth and engraftment capacity of CB-derived putative human HSCs (CD34 hi CD38 lo CD90 + CD45RAcells). 20 As indicated by receptor expression, CCL28 stimulated putative HSCs in a direct manner, demonstrated by increased cell numbers and progenitor activity compared to SCFtreated cultures ( Figure 2D -G). While TPO treatment outranged CCL28 stimulation with regard to overall proliferation potential, CCL28 maintained a higher frequency of the most primitive cell fractions ( Figure 2F ). Additionally, transplantation of CCL28-stimulated HSCs into NSG mice 21 yielded 62% engrafted recipients four weeks post transplant, whereas only 9% and 36% of the mice transplanted with SCFand TPO-treated cells, respectively, displayed human chimerism above 1% ( Figure   2H and table S2). Compared to equivalent numbers of fresh cells, CCL28-treated cells showed slightly lower short-term engraftment, indicating either a subtle loss of shortterm HSCs or delayed engraftment kinetics of the cultured cells ( Figure S5 ). By contrast, CCL28 treatment significantly improved long-term multilineage reconstitution levels compared to both fresh cells and cells cultured with SCF alone, demonstrating that the combined effect of SCF and CCL28 supports a net increase of long-term repopulating activity ( Figure 2I-K) . TPO-treated cells showed similar engraftment levels as CCL28, although not significantly increased compared to fresh cells. Collectively, these findings implicate CCL28 as a new, potent growth factor that supports the functional integrity of ex vivo-cultured HSPCs, placing it in a unique category of cytokines with HSC-supportive functions such as SCF and TPO.
To assess how CCL28 affects HSPCs in the context of a rich cytokine cocktail, we added it in combination with SCF, TPO and FLT3L ("STF") to cultures of CB CD34 + cells. STF conditions, in general, supported CFCs and led to elevated numbers of LTC-ICs compared to fresh cells, while NSG engraftment levels were markedly reduced ( Figure S6) , indicating a strong proliferative drive but poor maintenance of the most primitive cells. Addition of CCL28 to these conditions enhanced the output of early progenitors with mixed CFC potential, but did not rescue the adverse effects of STF stimulation on NSG reconstitution ability ( Figure S6 ). These findings illustrate the context-dependent function of growth factors and support the notion that multiple cytokine stimulation promotes proliferation at the expense of HSC activity. 9, 22 Thus, the further assessment of CCL28 to improve ex vivo culture conditions for HSPCs should be conducted in a systematic manner with other growth factor contexts and/or recently discovered molecules for HSC expansion. 3-6, 10, 23 Finally, given the presence of CCL28 in the BM microenvironment 24 (Figure S7 ), the potential role of CCL28 in regulating HSPCs in vivo as a niche-secreted factor under both normal and malignant 25 conditions represents another interesting topic for future studies. TNF  IGFBP4  IFNG  NRTN  APOE2  PTN  APOE3  XCL1  LTA  CCL20  FAM19A2  IL33  IL11  FGF18  IL4  NAMPT  CXCL5  ANGPT1  TNFRSF10A  CCL17  FGF16  APOA1  TNFSF12  FGF17  TSLP  PAFAH  ZGLP1  IL15  APOSAA  MSTNP  CD14  TNFSF15  CCL3L1  IL1B  IL1A 
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